RepliCel Life Sciences Empfehlungs-Mittelwert
Was ist das Empfehlungs-Mittelwert von RepliCel Life Sciences?
Empfehlungs-Mittelwert von RepliCel Life Sciences, Inc. ist 2.00
Was ist die Definition von Empfehlungs-Mittelwert?
Der empfohlene Mittelwert ist der Durchschnitt der Analystenbewertungen der Aktie von 1,0 (starker Kauf) bis 5,0 (starker Verkauf).
Mean of recommendations is an average of ratings from different analysts but it should still be used with other research and investment metrics in order to make investment decisions. It is important to understand a firm's entire scale when assimilating ratings. Additionally, analyst recommendations on stocks owned by firms employing them may be seen as potentially biased.
Financial analysts are often employed by mutual and pension funds, hedge funds, securities firms, banks, investment banks, insurance companies, and other businesses, helping these companies or their clients make investment decisions. Financial analysts employed in commercial lending perform "balance sheet analysis," examining the audited financial statements and corollary data in order to assess lending risks. In a stock brokerage house or in an investment bank, they read company financial statements and analyze commodity prices, sales, costs, expenses, and tax rates in order to determine a company's value and project future earnings. In any of these various institutions, the analyst often meets with company officials to gain a better insight into a company's prospects and to determine the company's managerial effectiveness.
Usually, financial analysts study an entire industry, assessing current trends in business practices, products, and industry competition. They must keep abreast of new regulations or policies that may affect the industry, as well as monitor the economy to determine its effect on earnings.
Empfehlungs-Mittelwert von Unternehmen in Health Care Sektor auf TSXV im Vergleich zu RepliCel Life Sciences
Was macht RepliCel Life Sciences?
RepliCel Life Sciences Inc., a regenerative medicine company, focuses on developing autologous cell therapies that treat functional cellular deficits. Its treatments use autologous cell therapy, which isolates an individual's own cells from harvested tissues and growing more in controlled conditions in a laboratory. The company's product candidates include RCT-01, which has completed Phase I clinical trials for the treatment of chronic tendinosis; RCS-01 that is in Phase 2 clinical trials to treat aging and sun damaged skin; and RCH-01, which is in Phase 2 clinical trials for the treatment of hair loss. It is also developing RCI-02, a dermal injection device. The company has a collaboration and technology transfer agreement with YOFOTO (China) Health Industry Co. Ltd. for establishing a clinical research program to develop and commercialize RCS-01 and RCT-01; and collaboration and technology transfer agreement with Shiseido Company, Limited for establishing a clinical research program for RCH-01. It also has a collaboration research project agreement with the University of British Columbia to build a hair follicle cell data map. RepliCel Life Sciences Inc. is headquartered in Vancouver, Canada.
Unternehmen mit empfehlungs-mittelwert ähnlich RepliCel Life Sciences
- Cabot Oil & Gas hat Empfehlungs-Mittelwert von 1.96
- Truist hat Empfehlungs-Mittelwert von 1.96
- Delta Air Lines hat Empfehlungs-Mittelwert von 1.96
- Discover Services hat Empfehlungs-Mittelwert von 1.96
- United Micro Electronics hat Empfehlungs-Mittelwert von 1.96
- Tapestry Inc hat Empfehlungs-Mittelwert von 1.97
- RepliCel Life Sciences hat Empfehlungs-Mittelwert von 2.00
- Trip.com Ltd hat Empfehlungs-Mittelwert von 2.03
- Sherwin-Williams Co hat Empfehlungs-Mittelwert von 2.03
- Canadian Pacific Kansas City hat Empfehlungs-Mittelwert von 2.03
- Arista Networks Inc hat Empfehlungs-Mittelwert von 2.03
- Anheuser-Busch InBev SA/NV hat Empfehlungs-Mittelwert von 2.03
- Celanese Corp hat Empfehlungs-Mittelwert von 2.04